CytoDyn takes major step forward filing trial protocol for HIV Monotherapy

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to bring news the company has filed to the FDA,  the pivotal trial protocol for leronlimab as a monotherapy for HIV patients. 

Pourhassan also shared details about the work involved to get to this point and what the next stage is.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $157.53 m

More on this story


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 16 hours ago

2 min read